Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
78Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.86B | $478.60M | $4.81 |
| 2024 | $2.36B | $341.30M | $3.40 |
| 2023 | $1.89B | $249.70M | $2.56 |
| 2022 | $1.49B | $154.50M | $1.61 |
| 2021 | $1.13B | $89.60M | $0.95 |
Social Signal Score
Earnings
Tue, Oct 27(in 2 months)
Consensus estimate $1.92 per share
Typical surprise +4.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.39 vs $1.65miss
- Tue, May 5$1.94 vs $1.22beat
- Wed, Feb 11$1.88 vs $1.80beat
- Tue, Oct 28$2.04 vs $1.58beat
- Wed, Jul 30$1.06 vs $0.98beat
- Mon, May 5$0.08 vs $0.54miss
Estimates and results for NBIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NBIX's reported EPS growth of 50.0% a year over 4 years. Historical EPS growth of 50% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $17.86
- Implied price
- $517.92
- Return from $152.72
- 27.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $257.50 — today's price is already 40.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| 20.0% | 10.5% | 14.4% | 17.8% | 20.9% | 23.7% |
| 25.0% | 15.1% | 19.2% | 22.8% | 26.0% | 28.9% |
| 30.0% | 19.7% | 23.9% | 27.7% | 31.0% | 34.0% |
| 35.0% | 24.3% | 28.7% | 32.6% | 36.0% | 39.2% |
| 40.0% | 28.9% | 33.5% | 37.5% | 41.1% | 44.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newsprnewswire.com·3d ago·Neutral
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes Mean improvements in the patien
View source ↗ - Newsreuters.com·3d ago·Negative
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported in patients with the rare genetic disorder.
View source ↗